-
Recent Posts
Categories
- Anesthesiology
- Avandia
- Biomedical Engineering
- Cardiology
- Clinical Trials
- Clinics
- Consumer Products
- Counterfeit Products
- Critical Care Medicine
- Dentistry
- Dermatology
- Emergency Rooms
- Endocrinology
- Eye Care
- Family Practice
- FDA 2011
- FDA 2012
- FDA 2013
- FDA Label Change
- FDA Notice
- FDA Recall
- FDA Safety Communication
- FDA Warning
- Gastroenterology
- Healthcare Professionals
- Hematology
- Home Care
- Hospitals
- Infectious Disease
- Internal Medicine
- Laboratory
- multiple sclerosis (MS)
- Nephrology
- Neurology
- Nursing
- OBGYN
- Oncology
- Ophthalmology
- Orthopaedic Surgery
- Pain Management
- Patients
- Pediatrics
- Pharmacy
- Physical Medicine
- Psychiatry
- Pulmonology
- Radiology
- Rheumatology
- Risk Manager
- Surgery
- Uncategorized
Archives
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
Category Archives: Internal Medicine
Incivek telaprevir Drug Safety Communication
Incivek (telaprevir) In Combination with Drugs Peginterferon Alfa and Ribavirin (Incivek Combination Treatment): Drug Safety Communication – Serious Skin Reactions AUDIENCE: Internal Medicine, Gastroenterology, Dermatology ISSUE: FDA received reports of serious skin reactions, some fatal, in patients taking the … Continue reading
Posted in Dermatology, FDA Label Change, FDA Safety Communication, Gastroenterology, Internal Medicine
Tagged Dermatology, Drug Safety Communication, Gastroenterology, Incivek, Incivek telaprevir Drug Safety Communication, Internal Medicine, Peginterferon Alfa, Ribavirin, Serious Skin Reactions, telaprevir
Comments Off
Xyrem sodium oxybate Drug Safety Communication
Xyrem (sodium oxybate): Drug Safety Communication – Warning Against Use With Alcohol or Drugs Causing Respiratory Depression AUDIENCE: Neurology, Internal Medicine, Patient ISSUE: FDA reminded healthcare professionals and patients that the combined use of Xyrem (sodium oxybate) with alcohol or … Continue reading
Posted in FDA 2012, FDA Safety Communication, Internal Medicine, Neurology, Patients
Tagged Drug Safety Communication, Internal Medicine, Neurology, Patient, sodium oxybate, Xyrem, Xyrem sodium oxybate Drug Safety Communication
Comments Off
Ampyra dalfampridine drug risks
Drug Safety Communication – Seizure Risk for Multiple Sclerosis Patients AUDIENCE: Neurology, Internal Medicine ISSUE: FDA is updating health care professionals and the public about the risk of seizures in patients with multiple sclerosis (MS) who are starting Ampyra (dalfampridine). … Continue reading
Posted in FDA 2012, FDA Safety Communication, FDA Warning, Internal Medicine, Neurology
Tagged Ampyra, Ampyra dalfampridine Drug Risks, dalfampridine, drug risks, Drug Safety Communication, FDA warning, Internal Medicine, MS, multiple sclerosis, Neurology, seizures
Comments Off
Aliskiren containing Medications Drug Safety Comunication
Aliskiren-containing Medications: Drug Safety Comunication – New Warning and Contraindication including: Amturnide (aliskiren hemifumarate, amlodipine besylate, and hydrochlorothiazide) Tekturna (aliskiren hemifumarate) Tekturna HCT (aliskiren hemifumarate and hydrochlorothiazide) Tekamlo (aliskiren hemifumarate and amlodipine besylate) Valturna (aliskiren hemifumarate and valsartan). Valturna will … Continue reading
Posted in Endocrinology, FDA 2012, FDA Safety Communication, Internal Medicine, Pharmacy
Tagged Aliskiren containing Medications, aliskiren hemifumarate, aliskiren hemifumarate and amlodipine besylate, aliskiren hemifumarate and hydrochlorothiazide, aliskiren hemifumarate and valsartan, amlodipine besylate, Amturnide, and hydrochlorothiazide, Drug Safety Communication, Endocrinology, fda, Internal Medicine, Pharmacy, Tekamlo, Tekturna, Tekturna HCT, Valturna
Comments Off